Peptide RX

back to claim graph

proof receipt / finding

Initial digest — Klotho-FGF23

AlphaFold v6 prediction landed for **Klotho-FGF23** (α-Klotho / FGF23 axis). UniProt accession: `Q9UEF7`. Lane: `longevity`. Mean per-residue pLDDT: **89.09**. Mimetics — peptide fragments shown to extend healthspan i...

grade C status literature receipt f162fd21d61b proof 33%

what this node claims

Initial digest — Klotho-FGF23

AlphaFold v6 prediction landed for **Klotho-FGF23** (α-Klotho / FGF23 axis). UniProt accession: `Q9UEF7`. Lane: `longevity`. Mean per-residue pLDDT: **89.09**. Mimetics — peptide fragments shown to extend healthspan i...

evidence / risk instrument

39%
thin proof
structure evidence gates risk export lineage 39
low debt pressure 29%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence
0.6
evidence refs
1

AlphaFold metrics visual

Confident backbone model

89.1

1012 residues / min 28.19 / max 98.81 / source alphafold db

PAE matrix for linked target
Very high 72.9% 738 residues / >=90
Confident 17.5% 177 residues / 70-89
Low 4.1% 41 residues / 50-69
Very low 5.5% 56 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 1012 of 1012 residues.

  • residues 1-33 / mean 37.0
  • residues 97-119 / mean 41.65
  • residues 957-979 / mean 56.7
  • residues 1007-1012 / mean 55.1
proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence
low computational-only status add independent evidence, challenge result, or witness review before strengthening
medium no candidate yet leave visible until a stronger public receipt resolves it

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
low evidence grade high blocks weakens attach graded finding with source-linked evidence
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

what supports it

evidence finding attached fold:eeefd326-126b-483a-8a74-9bf047523bf7 -> finding:ab0c94f3-d339-458f-a990-990031fbc616 supports / C / 0.6

what it supports

No downstream proof edge yet.

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.